Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats

Psychopharmacology

Volumn 231, Issue 13, 2014, Pages 2705-2716

  Hillhouse, Todd M ^a   Porter, Joseph H ^a   Negus, S Stevens ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bipolar; Cocaine; Depression; Intracranial self stimulation; Ketamine; MK 801; Rats

Indexed keywords

COCAINE; DIZOCILPINE; KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANESTHETIC AGENT; DIZOCILPINE MALEATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG EFFECT; DRUG TOLERANCE; MALE; MENTAL DISSOCIATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SELF STIMULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; MEDIAL FOREBRAIN BUNDLE; SPRAGUE DAWLEY RAT; SUBSTANCE-RELATED DISORDERS; TIME;

ANESTHETICS, DISSOCIATIVE; ANIMALS; COCAINE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; MEDIAL FOREBRAIN BUNDLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SELF STIMULATION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84903301599     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3451-3     Document Type: Article

References (73)

1. Altarifi AA, Negus SS (2011) Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence. Behav Pharmacol 22:663-673. doi: 10.1097/FBP.0b013e32834aff54
2. Altarifi AA, Miller LL, Negus SS (2012) Role of μ-opioid receptor reserve and μ-agonist efficacy as determinants of the effects of μ- agonists on intracranial self-stimulation in rats. Behav Pharmacol 23:678-692
3. Altarifi AA, Rice KC, Negus SS (2013) Abuse-related effects of μ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure. Behav Pharmacol 24:459-470. doi:10.1097/FBP.0b013e328364c0bd
4. Ardayfio PA, BenvengaMJ, Chaney SF, Love PL, Catlow J, Swanson SP, Marek GJ (2008) The 5-hydroxytryptamine2a receptor antagonist R-(+)-α- (2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4- piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther 327:891-897
5. Bauer CT, Banks ML, Blough BE, Negus SS (2013a) Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment. Behav Pharmacol 24:448-458. doi:10.1097/FBP. 0b013e328363d1a4
6. Bauer CT, Banks ML, Blough BE, Negus SS (2013b) Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol 168:850-862. doi: 10.1111/j.1476-5381.2012.02214.x
7. Beardsley PM, Hayes BA, Balster RL (1990) The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther 252:953-959 (Pubitemid 20127396)
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354 (Pubitemid 30109248)
9. Bespalov A, Lebedev A, Panchenko G, Zvartau E (1999) Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. Eur Neuropsychopharmacol 9:377-383 (Pubitemid 29415717)
10. Bonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS (2013) Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology. doi:10.1007/s00213-013-3223-5
11. Branch MN (1984) Rate dependency, behavioral mechanisms, and behavioral pharmacology. J Exp Anal Behav 42:511-522
12. Bresink I, DanyszW, Parsons CG, Mutschler E (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 34:533-540
13. Broadbear J, Winger G, Woods J (2004) Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology (Berl) 176:398-406 (Pubitemid 40012747)
14. Byrd LD (1982) Comparison of the behavioral effects of phencyclidine, ketamine, d-amphetamine and morphine in the squirrel monkey. J Pharmacol Exp Ther 220:139-144
15. Carlezon WA Jr, Chartoff EH (2007) Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995
16. Carlezon WA Jr, Wise RA (1993)Morphine-induced potentiation of brain stimulation reward is enhanced by MK-801. Brain Res 620:339-342
17. Carlezon WA, Wise RA (1996) Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 16:3112-3122
18. Corbett D (1989) Possible abuse potential of the NMDA antagonistMK- 801. Behav Brain Res 34:239-246
19. de la Peña JBI, Lee HC, de la Peña IC, Woo TS, Yoon SY, Lee HL et al (2012) Rewarding and reinforcing effects of the NMDA receptor antagonist - benzodiazepine combination, Zoletil® : difference between acute and repeated exposure. Behav Brain Res 233:434-442. doi:10.1016/j.bbr.2012.05. 038
20. De Luca M, Badiani A (2011) Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology (Berl) 214:549-556
21. De Vry J, Jentzsch KR (2003) Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol 14:229-235 (Pubitemid 36735156)
22. Diazgranados N, Ibrahim L, Brutsche NE et al (2010) A randomized addon trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802
23. Engin E, Treit D, Dickson CT (2009) Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 161:359-369
24. French ED (1994) Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol Teratol 16:355-362
25. Gilmour G, Pioli E, Dix S, Smith J, Conway M, Jones W, Loomis S, Mason R, Shahabi S, Tricklebank M (2009) Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl) 205:203-216
26. Grant KA, Colombo G, Grant J, Rogawski MA (1996) Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35:1709-1719 (Pubitemid 27090790)
27. Herberg LJ, Rose IC (1989) The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward. Psychopharmacology (Berl) 99:87-90 (Pubitemid 19201720)
28. Hillhouse TM, Porter JH (2014) Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement- of-low-rate operant schedule. Behav Pharmacol 25: 80-91. doi:10.1097/FBP. 0000000000000014
29. Hirota K, Hashimoto Y, Lambert DG (2002) Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in Chinese hamster ovary cells.Anesth Analg 95:1607-1610 (Pubitemid 35423948)
30. Institute of Laboratory Animal Resources (2011) Guide for the care and use of laboratory animals. 8th ed. Institute of Laboratory Animals Resources, Commission of Life Sciences, National Research Council, Washington DC
31. Katsidoni V, Kastellakis A, Panagis G (2013) Biphasic effects of Δ9- tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol 16:2273-2284
32. Kelleher RT, Morse WH (1968) Determinants of the specificity of behavioral effects of drugs. Ergeb Physiol 60:1-56
33. Kenny PJ, Gasparini F, Markou A (2003) Group II metabotropic and α- Amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/ kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306:1068-1076 (Pubitemid 37025315)
34. Killinger BA, Peet MM, Baker LE (2010) Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacol Biochem Behav 96:260-265
35. Koek W, Woods JH, Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969-974
36. Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111
37. Kornetsky C, Esposito RU, McLean S, Jacobson JO (1979) Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry 36:289-292 (Pubitemid 9125729)
38. Kwilasz AJ, Negus SS (2012) Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on painstimulated versus pain-depressed behavior in rats. J Pharmacol Exp Ther 343:389-400. doi:10.1124/jpet.112.197780
39. Lepore M, Liu X, Savage V, Matalon D, Gardner EL (1996) Genetic differences in Δ9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 58:365-372
40. Marquis KL, Moreton JE (1987) Animal models of intravenous phencyclinoid self-administration. Pharmacol Biochem Behav 27: 385-389 (Pubitemid 17106876)
41. McCambridge J,Winstock A, Hunt N,Mitcheson L (2007) 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res 13:57-64 (Pubitemid 44973727)
42. McMillan DE,Wright DW,Wenger GR (1992) Effects of phencyclidinelike drugs on responding under multiple fixed ratio, fixed interval schedules. Behav Pharmacol 3:143-147
43. Moreton JE, Meisch RA, Stark L, Thompson T (1977) Ketamine selfadministration by the rhesus monkey. J Pharmacol Exp Ther 203: 303-309
44. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan Het Rot M et al (2012) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250-256. doi:10.1016/j.biopsych.2012.06.022
45. Negus SS, Morrissey E, RosenbergM, Cheng K, RiceK(2010) Effects of kappa opioids in an assay of pain-depressed intracranial selfstimulation in rats. Psychopharmacology (Berl) 210:149-159
46. Negus SS, O'Connell R,Morrissey E, Cheng K, Rice KC (2012a) Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther 340:501-509. doi:10.1124/jpet.111.186783
47. Negus SS, RosenbergMB, Altarifi AA,O'Connell RH, Folk JE, Rice KC (2012b) Effects of the delta opioid receptor agonist SNC80 on painrelated depression of intracranial self-stimulation (ICSS) in rats. J Pain 13:317-327. doi:10.1016/j.jpain.2011.12.003
48. NishimuraM, SatoK, OkadaT,Yoshiya I, Schloss P,Shimada S, Tohyama M (1998) Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88:768-774 (Pubitemid 28120212)
49. Olds ME (1996) Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801. Eur J Pharmacol 306:23-32
50. Overton D, Shen CF, Ke G, Gazdick L (1989) Discriminable effects of phencyclidine analogs evaluated by multiple drug (PCP versus other) discrimination training. Psychopharmacology (Berl) 97: 514-520 (Pubitemid 19102555)
51. Páleníček T, Fujáková M, Brunovský M, Balíková M, Horáček J, Gorman I et al (2011) Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics. Neuropsychobiology 63:202-218
52. Pereira Do Carmo G, Stevenson GW, Carlezon WA, Negus SS (2009) Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain 144:170-177
53. Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, VittoMF, Cesconetto P, Souza CT, Quevedo J (2011) Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 221:166-171
54. Rocha BA, Ward AS, Egilmez Y, Lytle DA, Emmett-Oglesby MW (1996) Tolerance to the discriminative stimulus and reinforcing effects of ketamine. Behav Pharmacol 7:160-168 (Pubitemid 26122481)
55. Rosenberg MB, Carroll FI, Negus SS (2013) Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and paindepressed behavior in rats. J Pain 14:246-259. doi:10.1016/j.jpain.2012.11.006
56. Sanger DJ (1992) NMDA antagonists disrupt timing behaviour in rats. Behav Pharmacol 3:593-600
57. Sanger DJ, Blackman DE (1976) Rate-dependent effects of drugs: a review of the literature. Pharmacol Biochem Behav 4:73-83
58. Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877-883 (Pubitemid 43080122)
59. Shek DTL (2007) Tackling adolescent substance abuse in Hong Kong: where we should and should not go. Sci World J 7:2021-2030
60. Smith DJ, Bouchal RL, DeSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, Crisp T (1987) Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 26:1253-1260 (Pubitemid 17154877)
61. Stephens DN, Cole BJ (1996) AMPA antagonists differ from NMDA antagonists in their effects on operant DRL and delayed matching to position tasks. Psychopharmacology (Berl) 126:249-259 (Pubitemid 26252762)
62. Substance Abuse and Mental Health Services Administration (2013) Results from the 2012 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-46, HHS Publication No. (SMA) 13 - 4795. Rockville, MD: Substance Abuse and Mental Health Services Administration
63. SundstromJM, Hall FS, Stellar JR,Waugh EJ (2002) Effects of isolationrearing on intracranial self-stimulation reward of the lateral hypothalamus: baseline assessment and drug challenges. Life Sci 70: 2799-2810 (Pubitemid 34312013)
64. Suzuki T, Kato H, Aoki T, TsudaM, NaritaM,MisawaM(2000) Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice. Life Sci 67:383-389 (Pubitemid 30413919)
65. Vlachou S, Markou A (2011) Intracranial self-stimulation. In: Olmstead MC (ed) Animal models of drug addiction. Humana, Totowa, pp 3- 56
66. Wegener N, Nagel J, Gross R, Chambon C, Greco S, Pietraszek M, Gravius A, DanyszW (2011) Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour. Neurosci Lett 503:68-72
67. Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM (2012) The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 110:1762-1766
68. Wise RA (1996) Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319-340
69. Wise RA, Bauco P, CarlezonWA, TrojniarW(1992) Self-stimulation and drug reward mechanisms. Ann N YAcad Sci 654:192-198
70. Woolverton WL, Hecht GS, Agoston GE, Katz JL, Hauck Newman A (2001) Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology (Berl) 154:375- 382
71. Young AM,Woods JH (1981)Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different selfadministration histories. J Pharmacol Exp Ther 218:720-727 (Pubitemid 11005144)
72. Zarate CA Jr, Singh JB, Carlson PJ, BrutscheNE,Ameli R, Luckenbaugh DA et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864 (Pubitemid 44188478)
73. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939-946